Role of chondroitin 4-sulphate as a receptor for polycation induced human platelet aggregation
Autor(a) principal: | |
---|---|
Data de Publicação: | 1996 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.1996.tb16057.x/full http://repositorio.unifesp.br/handle/11600/43181 |
Resumo: | 1 Proteoglycans provide negatively charged sites on the surface of platelets, leukocytes and endothelial cells. Since chrondroitin 4-sulphate is the main proteoglycan present on the platelet surface, the role of this molecule in mediating the activation of human platelets by polylysine was studied. 2 Platelets were desensitized with phorbol 12-myristate 13-acetate (PMA, 10 nm) 5 min before the addition of polylysine to platelet-rich plasma (PRP). Changes in the intracellular Ca2+ concentration were measured in fura-2-am (2 mu M) loaded platelets and protein phosphorylation was assessed by autoradiography of the electrophoretic profile obtained from [P-32]-phosphate labelled platelets. The release of dense granule contents was measured in [C-14]-5-hydroxytryptamine loaded platelets and the synthesis of thromboxane (TXA(2)) was assessed by radioimmunoassay. Surface chrondroitinase AC (3 min, 37 degrees C). The amount of chondroitin-4-sulphate remained in the platelets was then quantified after proteolysis and agarose gel electrophoresis.3 The addition of PMA to PRP before polylysine inhibited the aggregation by 88+/-18% (n=3). Staurosporine (1 mu M, 5 min) prevented the PMA-induced inhibition. Chrondroitinase AC (4 pu ml(-1) to 400 mu u ml(-1), 3 min) abolished the polylysine-induced aggregation in PRP but caused only a discrete inhibition of ADP-induced aggregation. The concentration of chrondroitin 4-sulphate in PRP (0.96+/-0.2 mu g/10(8) platelets, n=3) and in washed platelets (WP; 0.35+/-0.1 mu g/10(8) platelets, n=3) was significantly reduced following incubation with chondroitinase AC (PRP=0.63+/-01 mu g/10(8) platelets and WP=0.08+/-0.06 mu g/10(8) platelets).4 Washed platelets had a significantly lower concentration of chrondroitin 4-sulphate than platelets in PRP. The addition of polylysine to WP induced a rapid increase in light transmission which was not accompanied by TXA(2) synthesis or the release of dense granule contents. This effect was not inhibited by sodium nitroprusside (SNP), iloprost, EDTA or the peptide RGDS. This event was accompanied by the discrete phosphorylation of plekstrin and myosin light chain, which were inhibited by staurosporine (10 mu M, 10 min). The hydrolysis of platelet surface chondroitin 4-sulphate strongly reduced the polylysine-induced phosphorylation.5 Our results indicate that polylysine activates platelets through a specific receptor which could be the proteoglycan chrondroitin 4-sulphate present on the platelet membrane. |
id |
UFSP_be032916d2ba141e371f549afd00b304 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/43181 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Role of chondroitin 4-sulphate as a receptor for polycation induced human platelet aggregationchondroitin 4-sulphatepolylysineprotein phosphorylationphorbol 12-myristate 13-acetate (PMA)calcium mobilization1 Proteoglycans provide negatively charged sites on the surface of platelets, leukocytes and endothelial cells. Since chrondroitin 4-sulphate is the main proteoglycan present on the platelet surface, the role of this molecule in mediating the activation of human platelets by polylysine was studied. 2 Platelets were desensitized with phorbol 12-myristate 13-acetate (PMA, 10 nm) 5 min before the addition of polylysine to platelet-rich plasma (PRP). Changes in the intracellular Ca2+ concentration were measured in fura-2-am (2 mu M) loaded platelets and protein phosphorylation was assessed by autoradiography of the electrophoretic profile obtained from [P-32]-phosphate labelled platelets. The release of dense granule contents was measured in [C-14]-5-hydroxytryptamine loaded platelets and the synthesis of thromboxane (TXA(2)) was assessed by radioimmunoassay. Surface chrondroitinase AC (3 min, 37 degrees C). The amount of chondroitin-4-sulphate remained in the platelets was then quantified after proteolysis and agarose gel electrophoresis.3 The addition of PMA to PRP before polylysine inhibited the aggregation by 88+/-18% (n=3). Staurosporine (1 mu M, 5 min) prevented the PMA-induced inhibition. Chrondroitinase AC (4 pu ml(-1) to 400 mu u ml(-1), 3 min) abolished the polylysine-induced aggregation in PRP but caused only a discrete inhibition of ADP-induced aggregation. The concentration of chrondroitin 4-sulphate in PRP (0.96+/-0.2 mu g/10(8) platelets, n=3) and in washed platelets (WP; 0.35+/-0.1 mu g/10(8) platelets, n=3) was significantly reduced following incubation with chondroitinase AC (PRP=0.63+/-01 mu g/10(8) platelets and WP=0.08+/-0.06 mu g/10(8) platelets).4 Washed platelets had a significantly lower concentration of chrondroitin 4-sulphate than platelets in PRP. The addition of polylysine to WP induced a rapid increase in light transmission which was not accompanied by TXA(2) synthesis or the release of dense granule contents. This effect was not inhibited by sodium nitroprusside (SNP), iloprost, EDTA or the peptide RGDS. This event was accompanied by the discrete phosphorylation of plekstrin and myosin light chain, which were inhibited by staurosporine (10 mu M, 10 min). The hydrolysis of platelet surface chondroitin 4-sulphate strongly reduced the polylysine-induced phosphorylation.5 Our results indicate that polylysine activates platelets through a specific receptor which could be the proteoglycan chrondroitin 4-sulphate present on the platelet membrane.UNIFESP,ESCOLA PAULISTA MED,DEPT BIOQUIM,BR-04044020 SAO PAULO,BRAZILUNIV FORMAT & RECH PHARM,U428 INSERM,PARIS,FRANCEUNIFESP,ESCOLA PAULISTA MED,DEPT BIOQUIM,BR-04044020 SAO PAULO,BRAZILWeb of ScienceStockton PressUniversidade Federal de São Paulo (UNIFESP)UNIV FORMAT & RECH PHARMDonato, José. L.Marcondes, SisiAntunes, EdsonNogueira, Marie Doki [UNIFESP]Dietrich, Carl Peter [UNIFESP]Rendu, F.deNucci, G.Nader, Helena Bonciani [UNIFESP]2018-06-15T16:24:08Z2018-06-15T16:24:08Z1996-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion1447-1453http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.1996.tb16057.x/fullBritish Journal Of Pharmacology. Basingstoke: Stockton Press, v. 119, n. 7, p. 1447-1453, 1996.0007-1188http://repositorio.unifesp.br/handle/11600/43181WOS:A1996VW40500021engBritish Journal Of Pharmacologyinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-05-02T15:52:09Zoai:repositorio.unifesp.br/:11600/43181Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-05-02T15:52:09Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
Role of chondroitin 4-sulphate as a receptor for polycation induced human platelet aggregation |
title |
Role of chondroitin 4-sulphate as a receptor for polycation induced human platelet aggregation |
spellingShingle |
Role of chondroitin 4-sulphate as a receptor for polycation induced human platelet aggregation Donato, José. L. chondroitin 4-sulphate polylysine protein phosphorylation phorbol 12-myristate 13-acetate (PMA) calcium mobilization |
title_short |
Role of chondroitin 4-sulphate as a receptor for polycation induced human platelet aggregation |
title_full |
Role of chondroitin 4-sulphate as a receptor for polycation induced human platelet aggregation |
title_fullStr |
Role of chondroitin 4-sulphate as a receptor for polycation induced human platelet aggregation |
title_full_unstemmed |
Role of chondroitin 4-sulphate as a receptor for polycation induced human platelet aggregation |
title_sort |
Role of chondroitin 4-sulphate as a receptor for polycation induced human platelet aggregation |
author |
Donato, José. L. |
author_facet |
Donato, José. L. Marcondes, Sisi Antunes, Edson Nogueira, Marie Doki [UNIFESP] Dietrich, Carl Peter [UNIFESP] Rendu, F. deNucci, G. Nader, Helena Bonciani [UNIFESP] |
author_role |
author |
author2 |
Marcondes, Sisi Antunes, Edson Nogueira, Marie Doki [UNIFESP] Dietrich, Carl Peter [UNIFESP] Rendu, F. deNucci, G. Nader, Helena Bonciani [UNIFESP] |
author2_role |
author author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) UNIV FORMAT & RECH PHARM |
dc.contributor.author.fl_str_mv |
Donato, José. L. Marcondes, Sisi Antunes, Edson Nogueira, Marie Doki [UNIFESP] Dietrich, Carl Peter [UNIFESP] Rendu, F. deNucci, G. Nader, Helena Bonciani [UNIFESP] |
dc.subject.por.fl_str_mv |
chondroitin 4-sulphate polylysine protein phosphorylation phorbol 12-myristate 13-acetate (PMA) calcium mobilization |
topic |
chondroitin 4-sulphate polylysine protein phosphorylation phorbol 12-myristate 13-acetate (PMA) calcium mobilization |
description |
1 Proteoglycans provide negatively charged sites on the surface of platelets, leukocytes and endothelial cells. Since chrondroitin 4-sulphate is the main proteoglycan present on the platelet surface, the role of this molecule in mediating the activation of human platelets by polylysine was studied. 2 Platelets were desensitized with phorbol 12-myristate 13-acetate (PMA, 10 nm) 5 min before the addition of polylysine to platelet-rich plasma (PRP). Changes in the intracellular Ca2+ concentration were measured in fura-2-am (2 mu M) loaded platelets and protein phosphorylation was assessed by autoradiography of the electrophoretic profile obtained from [P-32]-phosphate labelled platelets. The release of dense granule contents was measured in [C-14]-5-hydroxytryptamine loaded platelets and the synthesis of thromboxane (TXA(2)) was assessed by radioimmunoassay. Surface chrondroitinase AC (3 min, 37 degrees C). The amount of chondroitin-4-sulphate remained in the platelets was then quantified after proteolysis and agarose gel electrophoresis.3 The addition of PMA to PRP before polylysine inhibited the aggregation by 88+/-18% (n=3). Staurosporine (1 mu M, 5 min) prevented the PMA-induced inhibition. Chrondroitinase AC (4 pu ml(-1) to 400 mu u ml(-1), 3 min) abolished the polylysine-induced aggregation in PRP but caused only a discrete inhibition of ADP-induced aggregation. The concentration of chrondroitin 4-sulphate in PRP (0.96+/-0.2 mu g/10(8) platelets, n=3) and in washed platelets (WP; 0.35+/-0.1 mu g/10(8) platelets, n=3) was significantly reduced following incubation with chondroitinase AC (PRP=0.63+/-01 mu g/10(8) platelets and WP=0.08+/-0.06 mu g/10(8) platelets).4 Washed platelets had a significantly lower concentration of chrondroitin 4-sulphate than platelets in PRP. The addition of polylysine to WP induced a rapid increase in light transmission which was not accompanied by TXA(2) synthesis or the release of dense granule contents. This effect was not inhibited by sodium nitroprusside (SNP), iloprost, EDTA or the peptide RGDS. This event was accompanied by the discrete phosphorylation of plekstrin and myosin light chain, which were inhibited by staurosporine (10 mu M, 10 min). The hydrolysis of platelet surface chondroitin 4-sulphate strongly reduced the polylysine-induced phosphorylation.5 Our results indicate that polylysine activates platelets through a specific receptor which could be the proteoglycan chrondroitin 4-sulphate present on the platelet membrane. |
publishDate |
1996 |
dc.date.none.fl_str_mv |
1996-12-01 2018-06-15T16:24:08Z 2018-06-15T16:24:08Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.1996.tb16057.x/full British Journal Of Pharmacology. Basingstoke: Stockton Press, v. 119, n. 7, p. 1447-1453, 1996. 0007-1188 http://repositorio.unifesp.br/handle/11600/43181 WOS:A1996VW40500021 |
url |
http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.1996.tb16057.x/full http://repositorio.unifesp.br/handle/11600/43181 |
identifier_str_mv |
British Journal Of Pharmacology. Basingstoke: Stockton Press, v. 119, n. 7, p. 1447-1453, 1996. 0007-1188 WOS:A1996VW40500021 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
British Journal Of Pharmacology |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
1447-1453 |
dc.publisher.none.fl_str_mv |
Stockton Press |
publisher.none.fl_str_mv |
Stockton Press |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1814268409577209856 |